Given the extremely poor outcome of AML with either of these mutations, and the lack of current therapies directed against these variants, our data suggest a potential role for FAK inhibitors in treating AML with RUNX1 and possibly TP53 variants. This evidence concerns the gene RUNX1 and acute myeloid leukemia.